SCHEMBL5845812

SCHEMBL5845812

CN(C)c1ccsc1CC1CCCCC1(O)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.37
SLC6A2 P23975 3/20 0.37
SLC6A3 Q01959 2/20 0.37
OPRM1 P35372 3/20 0.37
OPRL1 P41146 2/20 0.37
STS P08842 1/20 0.35
KCNN4 O15554 2/20 0.34
OPRK1 P41145 4/20 0.34
OPRD1 P41143 2/20 0.34
EPHX1 P07099 2/20 0.33
S1PR2 O95136 1/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5845254 0.99 SLC6A4 (0.36) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
SCHEMBL5846585 0.86 SLC6A2 (0.38) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
Hydrochloric Acid SCHEMBL5845596 0.85 SLC6A2 (0.37) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
SCHEMBL5847461 0.85 SLC6A4 (0.39) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
Hydrochloric Acid SCHEMBL5845100 0.84 SLC6A4 (0.39) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
SCHEMBL5845811 0.72 SLC6A2 (0.38) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
Hydrochloric Acid SCHEMBL5845250 0.72 SLC6A2 (0.38) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
SCHEMBL6937427 0.71 TRPA1 (0.38) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
SCHEMBL5846576 0.70 SLC6A2 (0.40) SLC6A4SLC6A2SLC6A3OPRM1OPRL1
SCHEMBL5845804 0.69 KCNQ2 (0.39) SLC6A4SLC6A2SLC6A3OPRM1STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1253917-B1 USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS GRUENENTHAL GMBH (DE) 2005-02-16 EP claimed
EP-1043307-B1 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use GRUENENTHAL GMBH (DE) 2003-06-04 EP claimed
US-20030008859-A1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments GRUENENTHAL GMBH (DE) 2003-01-09 US claimed
US-6410790-B1 ANALGESICS GRUENENTHAL GMBH (DE) 2002-06-25 US claimed
US-7012099-B2 Using substituted 4-amino-1- phenylbutan-2-ol compounds in form of their racemates, enantiomers, diastereoisomers or corresponding bases or corresponding salts of acids as regulators for the nociceptin/orphanin FQ ligands in drugs GRUENENTHAL GMBH (DE) 2006-03-14 US disclosed
EP-1043307-B1 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use GRUENENTHAL GMBH (DE) 2003-06-04 EP disclosed
US-20030008859-A1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments GRUENENTHAL GMBH (DE) 2003-01-09 US disclosed
EP-1253917-A2 USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2002-11-06 EP disclosed
US-6410790-B1 ANALGESICS GRUENENTHAL GMBH (DE) 2002-06-25 US disclosed
WO-2001047506-A2 USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008859-A1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments OPRL1, OPRM1, OPRK1 SLC6A4 1019/4885SLC6A2 1098/4885SLC6A3 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.